Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 11/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184553 | 0.87 | PTGES (0.52) | PTGESBCHEAOC3BCL2TRIM24 | |
| SCHEMBL6032493 | 0.86 | PTGES (0.51) | PTGESAOC3BCL2HSD17B1HSD17B2 | |
| SCHEMBL2177213 | 0.82 | MEN1 (0.47) | PTGESBCHEAOC3BCL2TRIM24 | |
| SCHEMBL3948563 | 0.81 | AOC3 (0.57) | BCHEAOC3TRIM24TRIM33HSD17B1 | |
| SCHEMBL6185834 | 0.79 | AOC3 (0.58) | PTGESBCHEAOC3BCL2TRIM24 | |
| SCHEMBL6472820 | 0.79 | AOC3 (0.49) | PTGESBCHEAOC3HSD17B2DRD1 | |
| SCHEMBL6182236 | 0.77 | HSD17B2 (0.62) | BCHEAOC3HSD17B1HSD17B2 | |
| SCHEMBL6184104 | 0.76 | BCHE (0.53) | PTGESBCHEAOC3BCL2HSD17B1 | |
| SCHEMBL7025759 | 0.76 | GRIN2D (0.43) | PTGES | |
| SCHEMBL7021355 | 0.76 | PTGES (0.43) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | PTGES 520/4885BCHE 1768/4885AOC3 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.